EUVIMEDEUVIMED entdecken
Crossref

Harringtonine (HT) targets PARP-1 to inhibit TS mRNA m6A modification, blocks STAT3-induced miR-4521/TS axis and attenuates 5-fluorouracil (5-FU) resistance in NSCLC

Yu-Xi Qin, Yue-Ying Yang, Shi-Chen Zhang, Long-Tian Li, Ji-Fang Zhang, Ju-Bao Guo, Xin-Yang Li

Phytomedicine · 2025

DOI: 10.1016/j.phymed.2025.157148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytomedicine, 2025. Verfasst von Yu-Xi Qin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, 110004, PR China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Fluorouracil, Poly (ADP-Ribose) Polymerase-1, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: China International Medical Foundation, China Postdoctoral Science Foundation, China Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Harringtonine (HT), derived from the genus Cephalotaxus, has demonstrated anti-proliferative effects against non-small cell lung cancer (NSCLC). 5-Fluorouracil (5-FU), a cost-effective chemotherapy, faces resistance issues in NSCLC. Thus, exploring HT's mechanisms in inhibiting NSCLC proliferation and overcoming 5-FU resistance is clinically important. PURPOSE: This study aims to investigate for the first time the mechanism by which HT, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, attenuates 5-FU resistance in NSCLC. METHODS: Enzyme activity assay and surface plasmon resonance (SPR) were used to verify the HT's effects on PARP-1 activity. CCK-8, colony formation, drug affinity responsive target stability (DARTS), and cellular thermal shift assay (CETSA) were used to explore HT's ability to target PARP-1. Molecular docking, molecular dynamics, and one-point mutation assays explored the mode of action of HT with PARP-1. The anti-resistance effect of HT was assessed in vivo using regular and 5-FU-resistant NSCLC xenograft mice. The PARP-1-promoted 5-FU resistance mechanism in NSCLC was further explored by RNA immunoprecipitation (RIP), RNA pull-down, and co-immunoprecipitation (Co-IP) assays. Additional mechanisms of 5-FU resistance were explored through dual-luciferase assays and microRNA sequencing. RESULTS: HT effectively inhibited PARP-1 activity, downregulating thymidylate synthase (TS) in both regular and 5-FU-resistant xenograft models, thereby reducing NSCLC proliferation and resistance to 5-FU. Mechanistically, PARP-1 promoted the m6A modification of TS mRNA by binding to methyltransferase-like 3 (METTL3), thus increasing the stability of TS mRNA. Moreover, PARP-1 could inhibit the Activator of Transcription 3 (STAT3)-mediated expression of miR-4521 and promote the high expression of TS mRNA. This dual action mediated by PARP-1 ultimately promotes the resistance of NSCLC to 5-FU. CONCLUSION: These results demonstrated for the first time that HT was a novel PARP-1 inhibitor that inhibits 5-FU resistance in NSCLC, providing mechanistic clues and rational dosing recommendations for clinical treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungFluorouracilPoly (ADP-Ribose) Polymerase-1Drug Resistance, NeoplasmLung NeoplasmsThymidylate SynthasePhenanthrenesHumansAnimalsMicroRNAsMiceMice, NudeCell Line, TumorXenograft Model Antitumor AssaysMice, Inbred BALB CCell ProliferationRNA, MessengerPoly(ADP-ribose) Polymerase InhibitorsSTAT3 Transcription Factor

Stichwörter der Autor:innen

HarringtonineNSCLCPARP-1TS

Substanzen

FluorouracilPoly (ADP-Ribose) Polymerase-1MicroRNAsPARP1 protein, humanThymidylate SynthaseSTAT3 protein, humanPhenanthrenesRNA, MessengerN-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloridePoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, 110004, PR China.
  • Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, 110004, PR China. Electronic address: xinyanglicmu@163.com.

Förderung

  • China International Medical Foundation
  • China Postdoctoral Science Foundation
  • China Medical University
  • National Natural Science Foundation of China

Zitieren

APA

Qin, Y. X., Yang, Y. Y., Zhang, S. C., Li, L. T., Zhang, J. F., Guo, J. B., & Li, X. Y. (2025). Harringtonine (HT) targets PARP-1 to inhibit TS mRNA m6A modification, blocks STAT3-induced miR-4521/TS axis and attenuates 5-fluorouracil (5-FU) resistance in NSCLC. Phytomedicine. https://doi.org/10.1016/j.phymed.2025.157148

Vancouver

Qin YX, Yang YY, Zhang SC, Li LT, Zhang JF, Guo JB, et al. Harringtonine (HT) targets PARP-1 to inhibit TS mRNA m6A modification, blocks STAT3-induced miR-4521/TS axis and attenuates 5-fluorouracil (5-FU) resistance in NSCLC. Phytomedicine. 2025. doi:10.1016/j.phymed.2025.157148

BibTeX
@article{Qin2025,
  author = {Qin, Yu-Xi and Yang, Yue-Ying and Zhang, Shi-Chen and Li, Long-Tian and Zhang, Ji-Fang and Guo, Ju-Bao and Li, Xin-Yang},
  title = {Harringtonine (HT) targets PARP-1 to inhibit TS mRNA m6A modification, blocks STAT3-induced miR-4521/TS axis and attenuates 5-fluorouracil (5-FU) resistance in NSCLC},
  journal = {Phytomedicine},
  year = {2025},
  doi = {10.1016/j.phymed.2025.157148}
}
Kostenlos starten →